Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
Long non-coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B-cell lymphoma
Published in: British Journal of Haematology
Access to document
10.1111/bjh.18870
document
Gerben Duns, Melanie Winkle, Lauren Chong, Daisuke Ennishi, Ryan D Morin, Arjan Diepstra, David W Scott, Joost L Kluiver, Christian Steidl, Anke van den Berg
CRISPR/Cas9 screen for genome-wide interrogation of essential MYC-bound E-boxes in cancer cells
Published in: Molecular oncology
Access to document
10.1002/1878-0261.13493
document
The transcription factor MYC is a proto-oncogene with a well-documented essential role in the pathogenesis and maintenance of several types of cancer. MYC binds to specific E-box sequences in the genome to regulate gene expression in a cell-type- and developmental-stage-specific manner. To date, a combined analysis of essential MYC-bound E-boxes and their downstream target genes important for growth of different types of cancer is missing. In this study, we designed a CRISPR/Cas9 library to destroy E-box sequences in a genome-wide fashion. In parallel, we used the Brunello library...
Marta Kazimierska, Marta Podralska, Magdalena Żurawek, Tomasz Woźniak, Marta Elżbieta Kasprzyk, Weronika Sura, Wojciech Łosiewski, Iwona Ziółkowska-Suchanek, Joost Kluiver, Anke van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma
Published in: OncoImmunology
Access to document
10.1080/2162402X.2022.2033433
document
In classical Hodgkin lymphoma (cHL), the highly abundant CD4+ T cells in the vicinity of tumor cells are considered essential for tumor cell survival, but are ill-defined. Although they are activated, they consistently lack expression of activation marker CD26. In this study, we compared sorted CD4+CD26- and CD4+CD26+ T cells from cHL lymph node cell suspensions by RNA sequencing and T cell receptor variable gene segment usage analysis. This revealed that although CD4+CD26- T cells are antigen experienced, they have not clonally expanded. This may well be explained...
Johanna Veldman, Jessica Rodrigues Placa, Lauren Chong, Miente Martijn Terpstra, Mirjam Mastik, Leon C. van Kempen, Klaas Kok, Tomohiro Aoki, Christian Steidl, Anke van den Berg, Lydia Visser, Arjan Diepstra
Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers
Published in: Frontiers in endocrinology
Access to document
10.3389/fendo.2022.1006480
document
Introduction: Transformation from lung adenocarcinoma (LUAD) to small cell lung cancer (SCLC) is one of the mechanisms responsible for acquired EGFR-TKIs resistance. Although it rarely happens this event determines a rapid disease deterioration and needs specific treatment. Patient and method: We report a case of 75-year-old LUAD female with a p.L858R mutation in Epidermal Growth Factor Receptor (EGFR) who presented with SCLC transformation after responding to first line osimertinib treatment for only 6 months. To understand the underlying molecular mechanism, we retrospectively sequenced the first (LUAD) and the...
Jun Li, Bing Wei, Junnan Feng, Xinxin Wu, Yuxi Chang, Yi Wang, Xiuli Yang, Haiyan Zhang, Sile Han, Cuiyun Zhang, Jiawen Zheng, Harry J M Groen, Anke van den Berg, Jie Ma, Hongle Li, Yongjun Guo
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
Published in: Leukemia
Access to document
10.1038/s41375-022-01717-8
document
Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall...
HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC), Julia Driessen, Marie José Kersten, Lydia Visser, Anke van den Berg, Sanne H. Tonino, Josée M. Zijlstra, Pieternella J. Lugtenburg, Franck Morschhauser, Martin Hutchings, Sandy Amorim, Thomas Gastinne, Marcel Nijland, Gerben J.C. Zwezerijnen, Ronald Boellaard, Henrica C.W. de Vet, Anne I.J. Arens, Roelf Valkema, Roberto D.K. Liu, Esther E.E. DreesDaphne de Jong, Wouter J. Plattel, Arjan Diepstra